JP Morgan Week 2025 – Phil Johnson
Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP Morgan last month with pharmaphorum editor-in-chief Jonah Comstock to chat about why he joined up and his excitement about the company’s mission.
Johnson explains how Evidation creates an opt-in platform for patients to share their data for research purposes in exchange for rewards – and why the data that process creates is more valuable than the stores of data that researchers currently rely on. That includes a discussion of why data de-identification is a double-edged sword when it comes to RWD for drug developers.
The wide-ranging conversation also covers how AI is – and isn’t – changing data needs in drug discovery and why generative AI, fuelled by high-quality real-world data, is going to be bigger for disease prevention than for disease treatment.
It’s a long interview, but a good one, as Johnson brings a unique perspective to the exciting topic of real-world data, so stick around for the whole engaging conversation.
